Study
Location: Owensboro Health
Mitchell Memorial Cancer Center
1020 Breckenridge Street
Owensboro, KY 42303
Study Phase: Phase III
Cancer Type: Head and Neck Cancer
Purpose: This randomized Phase III clinical trial is to test whether the addition of cetuximab to radiation therapy will improve overall survival (OS) in postoperative patients with intermediate risk following head and neck surgery.
Enrollment and Eligibility:
Age: 18 years or older
Disease: Pathologically proven diagnosis of squamous cell carcinoma of the head/neck (oral cavity, oropharynx or larynx), with gross total resection of the primary tumor with curative intent must be completed within 7 weeks of registration.
Clinical stage T1, N1-2 or T2-4a, N0-2, M0 including no distant metastases.
Contact Person: Judy Strobel, RN, BSN, OCN, CCRP
Robin Osborne
Clinical Trials Coordinator
Phone: (270) 691-8094
(270) 688-1938
Fax: (270) 688-3673
Email: Judith.strobel@owensboro health.org
